

FILE 'USPAT' ENTERED AT 10:38:13 ON 04 AUG 1998

* WELCOME TO THE *
* U.S. PATENT TEXT FILE *

=> s diafiltr? or ultrafilt?
1187 DIAFILTR?
10914 ULTRAFILTR?
L1 11275 DIAFILTR? OR ULTRAFILTR?
=> s virus or viral or viruses
19266 VIRUS
15035 VIRAL
14781 VIRUSES
L2 27855 VIRUS OR VIRAL OR VIRUSES
=> s l1(p)l2
L3 326 L1(P)L2
=> s viscosity or viscous
175313 VISCOSITY
84491 VISCOUS
L4 218068 VISCOSITY OR VISCOUS
=> s l3(p)l4
L5 1 L3(P)L4
=> d
1. 4,855,285, Aug. 8, 1989, Antigenic modification of polypeptides;
Vernon C. Stevens, 514/12, 13; 930/20, 40, 110, 220 [IMAGE AVAILABLE]
=> s dnase# or dnase# or mase# or mase# or nuclease# or deoxyribonuclease# or
ribonuclease#
2059 DNASE#
274 DNASE#
3217 RNASE#
293 RNASE#
4090 NUCLEASE#
535 DEOXYRIBONUCLEASE#
2114 RIBONUCLEASE#
L6 8085 DNASE# OR DNASE# OR RNASE# OR RNASE# OR NUCLEASE#
OR DEOX
YRI
BONUCLEASE# OR RIBONUCLEASE#
=> s l1(p)l6
L7 73 L1(P)L6
=> s l7 and l2
L8 27 L7 AND L2
=> s l7(p)l2
L9 2 L7(P)L2
=> d l 2

1. 5,789,245, Aug. 4, 1998, Alphavirus structural protein expression
cassettes; Thomas W. Dubensky, Jr., et al., 435/320.1, 69.1, 325;
536/23.72 [IMAGE AVAILABLE]
2. 5,681,746, Oct. 28, 1997, Retroviral delivery of full length factor
VIII; Mordechai Bodner, et al., 435/350, 320.1, 366, 371; 536/23.5 [IMAGE
AVAILABLE]
=> d 1 2 kwic
US PAT NO: 5,789,245 [IMAGE AVAILABLE] L9: 1 of 2
DETDESC:
DETD(223)
The recombinant **virus** can also be preserved in a purified form. More
specifically, prior to the addition of the formulation buffer, the crude
recombinant **virus** described above may be clarified by passing it
through a filter and then concentrated, such as by a cross flow
concentrating system (Filtron Technology Corp., Norborough, Mass.).
Within one embodiment, **DNase** is added to the concentrate to digest
exogenous DNA. The digest is then **diafiltrated** in order to remove
excess media components and to establish the recombinant **virus** in a
more desirable buffered solution. The **diafiltrate** is then passed over
a Sephadex S-500 gel column and a purified recombinant **virus** is
eluted. A sufficient amount of formulation buffer is then added to this
eluate in order to reach a desired final concentration of the
constituents and to minimally dilute the recombinant **virus**. The
aqueous suspension may then be stored, preferably at -70 degree C., or
immediately dried. As above, the formulation buffer may . . .
US PAT NO: 5,681,746 [IMAGE AVAILABLE] L9: 2 of 2
DETDESC:
DETD(82)
Recombinant . . . filter, and then concentrated, such as by a cross
flow concentrating system (Filtron Technology Corp., Norborough, Mass.).
Within one embodiment, **DNase** is added to the concentrate to digest
exogenous DNA. The digest is then **diafiltrated** to remove excess media
components and establish the recombinant **virus** in a more desirable
buffered solution. The **diafiltrate** is then passed over a gel
filtration Sephadex S-500 gel column and a purified recombinant **virus**
is eluted.
=> d this

(FILE 'USPAT' ENTERED AT 10:38:13 ON 04 AUG 1998)

L1 11275 S DIAFILTR? OR ULTRAFILT?
 L2 27855 S VIRUS OR VIRAL OR VIRUSES
 L3 326 S L1(P)L2
 L4 218068 S VISCOSITY OR VISCOUS
 L5 1 S L3(P)L4
 L6 8085 S DNASE# OR DNASE# OR RNASE# OR RNAASE# OR
 NUCLEASE# OR D
 EOX

L7 73 S L1(P)L6
 L8 27 S L7 AND L2
 L9 2 S L7(P)L2
 => s ?virus
 L10 20272 ?VIRUS
 => s l7(p)l10
 L11 2 L7(P)L10
 => s l1(p)l10
 L12 204 L1(P)L10
 => s l4(p)l12
 L13 1 L4(P)L12
 => d

1. 4,855,285, Aug. 8, 1989, Antigenic modification of polypeptides;
 Vernon C. Stevens, 514/12, 13; 930/20, 40, 110, 220 [IMAGE AVAILABLE]

=> s microfil?

L14 2242 MICROFIL.T?

=> d his

(FILE 'USPAT' ENTERED AT 10:38:13 ON 04 AUG 1998)

L1 11275 S DIAFILTR? OR ULTRAFILT?
 L2 27855 S VIRUS OR VIRAL OR VIRUSES
 L3 326 S L1(P)L2
 L4 218068 S VISCOSITY OR VISCOUS
 L5 1 S L3(P)L4
 L6 8085 S DNASE# OR DNASE# OR RNASE# OR RNAASE# OR
 NUCLEASE# OR D
 EOX

L7 73 S L1(P)L6
 L8 27 S L7 AND L2
 L9 2 S L7(P)L2
 L10 20272 S ?VIRUS
 L11 2 S L7(P)L10
 L12 204 S L1(P)L10
 L13 1 S L4(P)L12
 L14 2242 S MICROFIL.T?
 => s l14(p)l10
 L15 24 L14(P)L10

=> s l6 and l15

L16 5 L6 AND L15

=> d l-5

1. 5,683,901, Nov. 4, 1997, Method of producing RNA viruses from cDNA;
 Vincent Racanietello, et al., 435/236; 424/217.1; 435/91.51, 172.1, 172.3,
 235.1; 536/23.72; 935/77 [IMAGE AVAILABLE]

2. 5,593,973, Jan. 14, 1997, Treatment of viral hepatitis with
 mismatched dsRNA; William A. Carter, 514/44; 435/6; 536/23.1 [IMAGE
 AVAILABLE]

3. 5,580,719, Dec. 3, 1996, Method for producing RNA viruses from cDNA;
 Vincent Racanietello, et al., 435/5, 6, 235.1; 935/77 [IMAGE AVAILABLE]

4. 5,554,498, Sep. 10, 1996, Nucleic acid amplification using scandium
 and lanthanum ions; Aaron G. Filler, et al., 435/5, 6, 91.2, 810 [IMAGE
 AVAILABLE]

5. 5,525,715, Jun. 11, 1996, Method for producing RNA viruses from cDNA;
 Vincent Racanietello, et al., 536/23.72; 424/185.1, 216.1, 217.1;
 435/172.3, 235.1 [IMAGE AVAILABLE]

=> d his

(FILE 'USPAT' ENTERED AT 10:38:13 ON 04 AUG 1998)

L1 11275 S DIAFILTR? OR ULTRAFILT?
 L2 27855 S VIRUS OR VIRAL OR VIRUSES
 L3 326 S L1(P)L2
 L4 218068 S VISCOSITY OR VISCOUS
 L5 1 S L3(P)L4
 L6 8085 S DNASE# OR DNASE# OR RNASE# OR RNAASE# OR
 NUCLEASE# OR D
 EOX

L7 73 S L1(P)L6
 L8 27 S L7 AND L2
 L9 2 S L7(P)L2
 L10 20272 S ?VIRUS
 L11 2 S L7(P)L10
 L12 204 S L1(P)L10
 L13 1 S L4(P)L12
 L14 2242 S MICROFIL.T?
 L15 24 S L14(P)L10
 L16 5 S L6 AND L15
 => s l3 and l6 not l7
 L17 31 L3 AND L6 NOT L7
 => d l-31

1. 5,789,216, Aug. 4, 1998, Cloning and expression of human GMP synthetase, its use in screening for inhibitors of human GMP synthetase and inhibitors of human GMP synthetase, Lillian Lien-Li Lou, et al., 435/183, 69.1, 252.3, 536/23.2, 24.31
2. 5,770,689, Jun. 23, 1998, Hepatitis E virus ORF 2 peptides; Gregory R. Reyes, et al., 530/324; 424/185.1, 189.1, 192.1, 225.1, 228.1; 530/350 [IMAGE AVAILABLE]
3. 5,741,490, Apr. 21, 1998, Hepatitis E virus vaccine and method; Gregory R. Reyes, et al., 424/189.1, 192.1, 193.1, 218.1, 228.1 [IMAGE AVAILABLE]
4. 5,723,755, Mar. 3, 1998, Large scale production of human or animal proteins using plant bioreactors; Marc G. Fortin, 800/205; 435/69.1, 69.52, 69.6, 70.1, 172.3, 320.1, 419; 536/24.1 [IMAGE AVAILABLE]
5. 5,714,374, Feb. 3, 1998, Chimeric rhinoviruses; Edward V. Arnold, et al., 435/235.1; 424/93.6; 435/172.3 [IMAGE AVAILABLE]
6. 5,686,239, Nov. 11, 1997, Hepatitis E virus peptides and methods; Gregory R. Reyes, et al., 435/5, 975; 436/518; 530/324, 403 [IMAGE AVAILABLE]
7. 5,683,901, Nov. 4, 1997, Method of producing RNA viruses from cDNA; Vincent Racaniello, et al., 435/236; 424/217.1; 435/91.51, 172.1, 172.3, 235.1; 536/23.72; 935/77 [IMAGE AVAILABLE]
8. 5,652,050, Jul. 29, 1997, Fibrous web for processing a fluid; David B. Pail, et al., 442/394; 428/315.5, 315.9, 318.4, 321.1, 903; 442/396 [IMAGE AVAILABLE]
9. 5,650,318, Jul. 22, 1997, Process and culture medium for the production of cells infected by a multiple sclerosis-associated virus; Herre Perron, et al., 435/372; 424/93.2, 184.1; 435/235.1, 239, 366, 373, 378, 404, 405 [IMAGE AVAILABLE]
10. 5,585,254, Dec. 17, 1996, Autonomous parvovirus gene delivery vehicles and expression vectors; Ian H. Maxwell, et al., 435/172.3; 424/93.2, 405; 435/69.1, 70.3, 91.1, 91.21, 91.3, 91.31, 91.32, 235.1, 320.1; 536/23.1, 23.7, 24.1, 24.5 [IMAGE AVAILABLE]
11. 5,580,719, Dec. 3, 1996, Method for producing RNA viruses from cDNA; Vincent Racaniello, et al., 435/5, 6, 235.1; 935/77 [IMAGE AVAILABLE]
12. 5,550,214, Aug. 27, 1996, Isolated antigenic oncogene peptide fragments and uses; Timothy J. Eberlein, et al., 530/328; 424/154.1, 155.1, 174.1, 184.1, 185.1, 277.1; 530/300, 403; 930/230 [IMAGE AVAILABLE]
13. 5,541,100, Jul. 30, 1996, Chimeric rhinoviruses; Edward V. Arnold, et al., 435/235.1; 424/93.6; 435/172.3 [IMAGE AVAILABLE]
14. 5,525,715, Jun. 11, 1996, Method for producing RNA viruses from cDNA; Vincent Racaniello, et al., 536/23.72; 424/185.1, 216.1, 217.1; 435/172.3, 235.1 [IMAGE AVAILABLE]
15. 5,478,730, Dec. 26, 1995, Method of preparing polypeptides in cell-free translation system; July B. Atkhov, et al., 435/68.1, 6, 69.1 [IMAGE AVAILABLE]
16. 5,462,751, Oct. 31, 1995, Biological and pharmaceutical agents having a nanometric biodegradable core; Nir Kossovsky, et al., 424/494, 93.6, 490, 493, 498; 514/2, 6, 951, 970 [IMAGE AVAILABLE]
17. 5,460,830, Oct. 24, 1995, Biochemically active agents for chemical catalysis and cell receptor activation; Nir Kossovsky, et al., 424/493, 94.3, 490, 494; 514/951, 970 [IMAGE AVAILABLE]
18. 5,434,079, Jul. 18, 1995, Apparatus and process for continuous in vitro synthesis of proteins; Bobak R. Mozayeni, 435/286.5; 210/321.75; 435/297.2; 935/88 [IMAGE AVAILABLE]
19. 5,427,664, Jun. 27, 1995, Free solution electrophoresis-membrane filters trapping assay apparatus and method; Stoyan V. Stoev, et al., 204/516, 462, 518, 542, 543, 613, 627 [IMAGE AVAILABLE]
20. 5,268,292, Dec. 7, 1993, Reproducible generation of high yields of hepatitis A virus by cell culture; Betty H. Robertson, et al., 435/239, 69.3, 91.33, 235.1; 536/23.72; 935/32, 34, 57, 65, 70 [IMAGE AVAILABLE]
21. 5,242,812, Sep. 7, 1993, Method for production and purification of hepatitis B vaccine; Zeev Even-Chen, 435/70.3; 424/227.1; 435/69.3; 530/395, 412, 414, 415, 416, 417, 806; 935/65 [IMAGE AVAILABLE]
22. 5,169,753, Dec. 8, 1992, Method and kit for detecting human retrovirus; Valerie L. Ng, et al., 435/5, 7.1, 235.1, 239, 810, 948, 975 [IMAGE AVAILABLE]
23. 5,108,920, Apr. 28, 1992, Retrovirus isolated from human lymphoma cell lines; Valerie L. Ng, et al., 435/239, 235.1, 372 [IMAGE AVAILABLE]
24. 5,106,745, Apr. 21, 1992, Broad spectrum virus inhibitor,

UTL-beta.; Samuel Baron, et al., 435/375; 514/2, 8; 530/350, 380, 395
[IMAGE AVAILABLE]

25. 5,069,901, Dec. 3, 1991, Preparation of a recombinant subunit
vaccine against pseudorabies infection; Elaine V. Jones, et al.,
424/199.1, 223.1, 229.1, 278.1, 283.1; 435/5, 172.3, 235.1, 238, 320.1;
530/826; 935/59, 63 [IMAGE AVAILABLE]

26. 4,789,702, Dec. 6, 1988, Feline leukemia virus vaccine; Jack H.
Nunberg, 530/324; 424/187.1; 435/69.3, 69.7; 514/2, 14; 530/327, 350,
402, 405, 806, 812, 820, 930/220, 300; 935/60, 109 [IMAGE AVAILABLE]

27. 4,724,146, Feb. 9, 1988, Method for preparation herpes simplex virus
subunit vaccine; Youichiro Kino, et al., 424/231.1; 435/235.1, 239;
530/412, 826 [IMAGE AVAILABLE]

28. 4,701,416, Oct. 20, 1987, Feline leukemia virus vaccine plasmids for
fusion protein of the gp70 envelope protein of FELV; Jack H. Nunberg,
435/320.1, 69.7, 172.3; 530/808, 820, 826; 536/23.4; 930/10, 220; 935/27,
29, 38, 47, 73 [IMAGE AVAILABLE]

29. 4,661,349, Apr. 28, 1987, Herpes simplex virus subunit vaccine;
Yoichiro Kino, et al., 424/231.1; 435/235.1, 236, 238, 239; 530/388.3
[IMAGE AVAILABLE]

30. 4,469,685, Sep. 4, 1984, Process for producing interferon inducers;
Yasuhiko Kojima, et al., 424/195.1 [IMAGE AVAILABLE]

31. 4,239,714, Dec. 16, 1980, Method for modifying the pore size
distribution of a microporous separation medium; Robert E. Sparks, et
al., 264/45.5; 210/500.21, 500.25, 500.28, 500.36, 500.38; 264/41, 129,
321, 340, DIG.13, DIG.18 [IMAGE AVAILABLE]
=> d his

(FILE 'USPAT' ENTERED AT 10:38:13 ON 04 AUG 1998)

L1 11275 S DIAFILTR? OR UL TRAFIL.T?
L2 27855 S VIRUS OR VIRAL OR VIRUSES
L3 326 S L1(P)L2
L4 218068 S VISCOSITY OR VISCOUS
L5 1 S L3(P)L4
L6 8085 S DNASE# OR DNASE# OR RNASE# OR RNASE# OR
NUCLEASE# OR D
EOX

L7 73 S L1(P)L6
L8 27 S L7 AND L2
L9 2 S L7(P)L2
L10 20272 S ?VIRUS

L11 2 S L7(P)L10
L12 204 S L1(P)L10
L13 1 S L4(P)L12

L14 2242 S MICROFIL.T?

L15 24 S L14(P)L10

L16 5 S L6 AND L15

L17 31 S L3 AND L6 NOT L7

=> s influenza? or adeno?

4055 INFLUENZA?

12103 ADENO?

L18 14941 INFLUENZA? OR ADENO?

=> s 118(p)6

L19 276 L18(P)L6

=> s 12(p)119

L20 84 L2(P)L19

=> d his

(FILE 'USPAT' ENTERED AT 10:38:13 ON 04 AUG 1998)

L1 11275 S DIAFILTR? OR UL TRAFIL.T?

L2 27855 S VIRUS OR VIRAL OR VIRUSES

L3 326 S L1(P)L2

L4 218068 S VISCOSITY OR VISCOUS

L5 1 S L3(P)L4

L6 8085 S DNASE# OR DNASE# OR RNASE# OR RNASE# OR
NUCLEASE# OR D

EOX

L7 73 S L1(P)L6

L8 27 S L7 AND L2

L9 2 S L7(P)L2

L10 20272 S ?VIRUS

L11 2 S L7(P)L10

L12 204 S L1(P)L10

L13 1 S L4(P)L12

L14 2242 S MICROFIL.T?

L15 24 S L14(P)L10

L16 5 S L6 AND L15

L17 31 S L3 AND L6 NOT L7

L18 14941 S INFLUENZA? OR ADENO?

L19 276 S L18(P)L6

L20 84 S L2(P)L19

=> s lysis or lysed or lysing

8190 LYSIS

6966 LYSIED

2878 LYSING

L21 12760 LYSIS OR LYSIED OR LYSING

=> s 121(p)6

L22 894 L21(P)L6

- => s118 and L22
 L23 352 L18 AND L22
 => s118(p)L22
 L24 6 L18(P)L22
 => d1-6
1. 5,591,717, Jan. 7, 1997, Branched apogenic peptide for inducing apoptosis; Jennifer L. Rojko, et al., 514/12; 435/29; 514/13, 14, 15, 16, 17; 530/324, 325, 326, 327, 328, 329 [IMAGE AVAILABLE]
2. 5,104,854, Apr. 14, 1992, Antiviral peptides; Milton J. Schlesinger, et al., 514/15; 530/328 [IMAGE AVAILABLE]
3. 5,026,839, Jun. 25, 1991, DNA encoding a basic fibroblast growth factor; David A. Moscatelli, et al., 536/23.51; 435/69.4, 320.1; 530/399; 536/23.5 [IMAGE AVAILABLE]
4. 4,994,559, Feb. 19, 1991, Human basic fibroblast growth factor, David A. Moscatelli, et al., 530/399, 350, 851 [IMAGE AVAILABLE]
5. 4,983,522, Jan. 8, 1991, Method for producing the HinfI restriction endonuclease and methylase; Janet M. Barsomian, et al., 435/172.3, 199, 252.33, 320.1; 536/23.2; 935/29, 73, 80, 82 [IMAGE AVAILABLE]
6. 4,568,640, Feb. 4, 1986, Method of inserting amino acid analogs into proteins; Harvey Rubin, 435/69.4, 69.1, 69.3, 69.5, 69.51, 69.52; 530/302, 808, 935/3, 20, 111 [IMAGE AVAILABLE]
 => d his
- (FILE TUSPAT ENTERED AT 10:38:13 ON 04 AUG 1998)
- L1 11275 S DIAFILTR? OR ULTRAFILT?
 L2 27855 S VIRUS OR VIRAL OR VIRUSES
 L3 326 S L1(P)L2
 L4 218068 S VISCOSITY OR VISCOUS
 L5 1 S L3(P)L4
 L6 8085 S DNASE# OR DNASE# OR RNASE# OR RNAASE# OR NUCLEASE# OR D
 EOX
 L7 73 S L1(P)L6
 L8 27 S L7 AND L2
 L9 2 S L7(P)L2
 L10 20272 S ?VIRUS
 L11 2 S L7(P)L10
 L12 204 S L1(P)L10
 L13 1 S L4(P)L12
 L14 2242 S MICROFILT?
 L15 24 S L14(P)L10
- L16 5 S L6 AND L15
 L17 31 S L3 AND L6 NOT L7
 L18 14941 S INFLUENZA? OR ADENO?
 L19 276 S L18(P)L6
 L20 84 S L2(P)L19
 L21 12760 S LYSIS OR LYSSED OR LYSING
 L22 894 S L21(P)L6
 L23 352 S L18 AND L22
 L24 6 S L18(P)L22
 => s12(p)L22
 L25 32 L2(P)L22
 => d1-32
1. 5,770,427, Jun. 23, 1998, Retrovirus from the HIV group and its use; Luiz G. Guertler, et al., 435/235.1; 424/148.1, 160.1, 188.1, 208.1; 435/5, 236; 530/388.35, 389.4; 536/23.72 [IMAGE AVAILABLE]
2. 5,759,770, Jun. 2, 1998, Retrovirus from the HIV group and its use; Luiz G. Guertler, et al., 435/5; 424/148.1, 160.1, 188.1, 208.1; 435/235.1, 236; 530/388.35, 389.4; 536/23.72 [IMAGE AVAILABLE]
3. 5,728,379, Mar. 17, 1998, Tumor- or cell-specific herpes simplex virus replication; Robert L. Martuza, et al., 424/93.2; 435/172.3, 320.1; 935/22, 32 [IMAGE AVAILABLE]
4. 5,721,354, Feb. 24, 1998, Human cytomegalovirus DNA sequences; Richard Spaete, et al., 536/23.72; 424/230.1; 435/5, 69.3, 172.3, 252.3, 320.1 [IMAGE AVAILABLE]
5. 5,693,535, Dec. 2, 1997, HIV targeted ribozymes; Kenneth G. Draper, et al., 435/372.3, 6, 91.31, 172.3, 325, 366; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
6. 5,683,866, Nov. 4, 1997, Process for producing a targeted gene; Debi P. Sarkar, et al., 435/5, 238, 239, 370 [IMAGE AVAILABLE]
7. 5,679,774, Oct. 21, 1997, DNA sequences of the EBV genome, recombinant DNA molecules, processes for preparing EBV-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens; Hans J. Wolf, 530/350; 424/185.1, 196.11, 230.1; 530/300, 395; 536/23.72 [IMAGE AVAILABLE]
8. 5,643,715, Jul. 1, 1997, Human papillomavirus type 52 DNA sequences and methods for employing the same; Wayne D. Lancaster, 435/5, 6, 320.1; 536/23.72, 24.3 [IMAGE AVAILABLE]
9. 5,627,048, May 6, 1997, Aedes aegypti densovirus expression system;

- Boris N. Afanasiev, et al., 435/69.1, 320.1, 348 [IMAGE AVAILABLE]
10. 5,622,854, Apr. 22, 1997, Method and reagent for inhibiting T-cell leukemia virus replication; Kenneth G. Draper, 435/366, 6, 91.31, 172.3, 320.1, 325, 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
11. 5,622,705, Apr. 22, 1997, Encapsidated recombinant poliovirus nucleic acid and methods of making and using same; Casey D. Morrow, 424/199.1, 208.1, 217.1; 435/69.3, 172.1, 320.1 [IMAGE AVAILABLE]
12. 5,620,881, Apr. 15, 1997, Gene encoding mutant L3T4 protein which facilitates HIV infection and transgenic mouse expressing such protein; Kenneth J. Wieder, et al., 435/172.3, 69.1, 320.1, 354, 355, 357; 536/23.5; 935/70 [IMAGE AVAILABLE]
13. 5,614,413, Mar. 25, 1997, Encapsidated recombinant poliovirus nucleic acid and methods of making and using same; Casey D. Morrow, 435/320.1, 69.3, 172.1 [IMAGE AVAILABLE]
14. 5,610,054, Mar. 11, 1997, Enzymatic RNA molecule targeted against Hepatitis C virus; Kenneth G. Draper, 435/363, 6, 91.31, 320.1, 325, 366; 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
15. 5,604,098, Feb. 18, 1997, Methods and materials for restriction endonuclease applications; David Mead, et al., 435/6, 91.1, 91.2, 172.1, 810; 536/23.1, 24.32, 24.33, 25.3, 25.32; 935/77, 78 [IMAGE AVAILABLE]
16. 5,604,093, Feb. 18, 1997, Human herpesvirus-6(1-HV-6) isolation and Products; Syed Z. Salahuddin, et al., 435/5, 6, 91.2; 536/23.1, 24.3, 24.32 [IMAGE AVAILABLE]
17. 5,585,096, Dec. 17, 1996, Replication-competent herpes simplex virus mediates destruction of neoplastic cells; Robert L. Martuza, et al., 424/93.2, 205.1, 229.1; 435/172.3, 235.1, 236, 320.1; 935/32 [IMAGE AVAILABLE]
18. 5,567,603, Oct. 22, 1996, HIV-3 retrovirus and its use; Robert De Lays, et al., 435/235.1, 5, 6, 69.3, 974; 536/23.72, 24.1 [IMAGE AVAILABLE]
19. 5,543,319, Aug. 6, 1996, Recombination-proficient avian/mammalian microcell hybrids; R. E. Keith Fournier, et al., 435/349, 424/93.3; 435/70.2, 172.2; 935/93, 96, 106 [IMAGE AVAILABLE]
20. 5,512,430, Apr. 30, 1996, Diagnostic array for virus infection; Yu Gong, 435/5, 6, 91.32, 91.33, 974; 536/24.33; 935/1, 16, 19, 20, 77 [IMAGE AVAILABLE]
21. 5,462,734, Oct. 31, 1995, Bovine herpesvirus vaccine and method of using same; Geoffrey J. Leitchworth, III, et al., 424/229.1, 813; 435/69.3; 530/395 [IMAGE AVAILABLE]
22. 5,443,964, Aug. 22, 1995, Poxvirus insertion/expression vector; David J. Pickup, et al., 435/69.1, 235.1, 320.1, 366; 536/24.1; 935/32, 34, 70 [IMAGE AVAILABLE]
23. 5,304,466, Apr. 19, 1994, HIV-3 retrovirus and its use; Robert De Lays, et al., 435/5, 69.1, 172.3, 235.1, 974, 975 [IMAGE AVAILABLE]
24. 5,165,925, Nov. 24, 1992, Vaccine for immunizing fish against infectious pancreatic necrosis virus; Jo-ann C. Leong, 424/186.1, 204.1, 817; 435/69.3; 536/23.72 [IMAGE AVAILABLE]
25. 5,153,181, Oct. 6, 1992, Pharmaceutical compositions comprising organic polymers containing inorganic anionic groups and method of prophylaxis and treatment of retrovirus infections in mammals using said compositions; Heino Diringier, et al., 514/54, 59, 885; 536/54, 112, 123 [IMAGE AVAILABLE]
26. 5,122,447, Jun. 16, 1992, Method of detecting pseudorabies virus specific serum antibody by use of a universal diagnostic antigen; Michael J. McGinty, et al., 435/5; 424/229.1; 435/7.92, 235.1; 436/543 [IMAGE AVAILABLE]
27. 5,104,854, Apr. 14, 1992, Antiviral peptides; Milton J. Schlesinger, et al., 514/15; 530/328 [IMAGE AVAILABLE]
28. 5,093,258, Mar. 3, 1992, Recombinant fowlpox virus and recombination vector; Lawrence K. Cohen, et al., 435/235.1; 424/199.1, 232.1; 435/172.3, 320.1; 935/6, 32, 65 [IMAGE AVAILABLE]
29. 5,041,447, Aug. 20, 1991, Oxetamycin-related compounds and pharmaceutical compositions containing them; Seichi Saito, et al., 514/262, 265, 266; 544/265, 267, 276, 277 [IMAGE AVAILABLE]
30. 4,935,342, Jun. 19, 1990, Method of isolating and purifying nucleic acids from biological samples; David B. Seligson, et al., 435/6, 270, 803; 436/17; 536/25.4, 25.41, 25.42; 935/1, 9, 19, 20, 21, 77 [IMAGE AVAILABLE]
31. 4,894,228, Jan. 16, 1990, Vaccine against hepatitis A virus; Robert H. Purcell, et al., 424/189.1, 226.1; 435/172.1, 172.3, 236; 514/894; 536/23.72 [IMAGE AVAILABLE]

32. 4,104,126, Aug. 1, 1978, Non-isotopic substrate assay employing
bacteriolytic products; David M. Young, 435/5, 4, 6, 7.32, 7.37, 7.4, 8,
18 [IMAGE AVAILABLE]

=> log hold

SESSION WILL BE HELD FOR 30 MINUTES

U.S. Patent & Trademark Office SESSION SUSPENDED AT 11:07:35 ON 04 AUG 199
8

Connection closed by remote host